Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 February 2024 | Story Leonie Bolleurs | Photo SUPPLIED
Action Learning Workshop 2024
Along with Prof Richard Teare (far right) are some of the workshop attendees, which consisted of a group of 15 students, academics, and community organisation leaders.

The Directorate Community Engagement at the University of the Free State (UFS) recently hosted Prof Richard Teare, the President of the Global University of Lifelong Learning (GULL). During his visit, he presented a workshop on action learning.

GULL, established 17 years ago, offers lifelong learning opportunities for people in communities and workplace organisations around the world. It provides frameworks and awards in support of lifelong learning.

Prof Teare described what the process of action learning entails and how it differs from the notion of ‘training’. According to him, action learning occurs when people learn from each other, create their own resources, identify their own problems, and form their own solutions. He stated, “The process is so enriching that every learner is able to identify personal and life-transforming outcomes. These commonly include expressions of enhanced self-confidence, self-belief, renewal, enthusiasm for learning, a new sense of direction and purpose for career and life – along with news skills, insights, and the sense of being equipped for the future.”

The workshop, attended by a group of 15 students, academics, and community organisation leaders, had an element of self-directed development, according to Dr Karen Venter, Head of the Division of Service Learning at the University of the Free State (UFS). “Participants learned how action learning can enable self-directed personal and professional development,” she said.

Skills and leadership characteristics

GULL pathways were also profiled to outline some of the innovative ways in which it can be used to facilitate continuous development aligned with professional certification. It offers three generic pathways, each with five levels (or certification points) leading to professional bachelor’s, master’s, and doctoral degrees,” explained Dr Venter.

“In practice, community leaders who have obtained one of these professional degrees can now become change agents for community development in their own community organisations, using the action learning pathway and certification offered by GULL,” she said.

Dr Venter added that a group of students from the UFS – the Active Community Citizens through Engaged Scholarship for Sustainability (ACCESS) group – embarked on a Professional Bachelor pathway certified by GULL last year. Not only did the group of 11 students successfully earn certification, including one Level Two certificate, five Level Three diplomas, three advanced diplomas, and one bachelor’s degree at the Engaged Scholarship Awards 2023, but they also developed a range of skills and leadership characteristics during the process. These include eco-brick making, vermiculture and gardening, eco-entrepreneurship, soap and candle making, and creative recycling, to name a few. 

Furthermore, the pathway is underpinned by community-based research to drive initiatives of student structures towards implementing impactful community engagement in three clusters, namely sustainable environment, well-being, and social justice.

Addressing SDGs and embracing Vision 130

Lifelong action learning is one of the innovative approaches for the development of graduate attributes. In this light, the outcomes of not only the action learning workshop, but also the learning opportunities presented by GULL, align with the UFS Vision130. “Using action learning for bringing social change, students can address the United Nations Sustainable Development Goals (SDGs) and embrace the values of the UFS’ Vision130 – impact, care, excellence, sustainability, accountability, and social justice,” stated Dr Venter.

One of the attendees communicated the experience as follows: “I learned that action learning is a process for self-determined personal and professional development – the change starts with me developing myself and then sharing it with others.” 

For further opportunities presented by GULL, visit the website here.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept